 <h1>Vismodegib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to vismodegib: oral capsule</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Vismodegib can result in embryo-fetal death or severe birth defects when administered to a pregnant woman. Animal data indicate vismodegib is embryotoxic, fetotoxic, and teratogenic. Pregnancy status should be verified 7 days prior to treatment initiation. Advise pregnant women of the potential risks to a fetus. Advise female patients to use effective contraception during and after vismodegib therapy. Advise male patients of the potential risk of vismodegib exposure through semen and recommend use of condoms with a pregnant partner or female partner of reproductive potential.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, vismodegib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking vismodegib:</p><p>
<i>Less common</i>
</p><ul>
<li>Bloody or cloudy urine</li>
<li>confusion</li>
<li>decreased urine output</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fast or irregular heartbeat</li>
<li>headache</li>
<li>increased thirst</li>
<li>loss of consciousness</li>
<li>muscle pain or cramps</li>
<li>nausea</li>
<li>pain in the lower back or side</li>
<li>seizures</li>
<li>swelling of the face, ankles, or hands</li>
<li>thirst</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blistering, peeling, loosening of the skin</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>itching skin</li>
<li>joint or muscle pain</li>
<li>painful or difficult urination</li>
<li>red irritated eyes</li>
<li>red skin lesions, often with a purple center</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>sore throat</li>
<li>swollen glands</li>
<li>trouble breathing</li>
<li>unusual bleeding or bruising</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of vismodegib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Absent, missed, or irregular menstrual periods</li>
<li>change in taste</li>
<li>constipation</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>difficulty having a bowel movement</li>
<li>difficulty with moving</li>
<li>hair loss or thinning</li>
<li>loss of taste</li>
<li>muscle spasm or stiffness</li>
<li>pain in the joints</li>
<li>stopping of menstrual bleeding</li>
<li>weight loss</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to vismodegib: oral capsule</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (64%), pruritus</p>
<p><b>Common</b> (1% to 10%): Rash, madarosis, abnormal hair growth </p>
<p><b>Postmarketing reports</b>: Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia, systemic symptoms<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (31%), diarrhea (29%), constipation (21%), vomiting (14%)</p>
<p><b>Common</b> (1% to 10%): Dyspepsia, upper abdominal pain, abdominal pain<sup>[Ref]</sup></p><h3>General</h3><p>The most frequent adverse drug reactions reported were muscle spasms (75%), alopecia (65%), dysgeusia (57%), weight loss (49%), fatigue (45%), and nausea (35%).<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Amenorrhea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight loss (45%), decreased appetite (25%)</p>
<p><b>Common</b> (1% to 10%): Dehydration, hyponatremia, azotemia, and hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Muscle spasms (72%), arthralgia (16%)</p>
<p><b>Common</b> (1% to 10%): Pain in extremity, back pain, musculoskeletal chest pain, myalgia, flank pain, musculoskeletal pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (55%), ageusia (11%)</p>
<p><b>Common</b> (1% to 10%): Hypogeusia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatic enzymes increased </p>
<p><b>Postmarketing reports</b>: Drug-induced liver injury<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (40%)</p>
<p><b>Common</b> (1% to 10%): Pain, asthenia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Elevated blood urea nitrogen<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Erivedge (vismodegib)." Genentech, South San Francisco, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about vismodegib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: hedgehog pathway inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vismodegib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Erivedge</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Basal Cell Carcinoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to vismodegib: oral capsule</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (64%), pruritus</p><p><b>Common</b> (1% to 10%): Rash, madarosis, abnormal hair growth </p><p><b>Postmarketing reports</b>: Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia, systemic symptoms<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (31%), diarrhea (29%), constipation (21%), vomiting (14%)</p><p><b>Common</b> (1% to 10%): Dyspepsia, upper abdominal pain, abdominal pain<sup>[Ref]</sup></p><h3>General</h3><p>The most frequent adverse drug reactions reported were muscle spasms (75%), alopecia (65%), dysgeusia (57%), weight loss (49%), fatigue (45%), and nausea (35%).<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Amenorrhea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight loss (45%), decreased appetite (25%)</p><p><b>Common</b> (1% to 10%): Dehydration, hyponatremia, azotemia, and hypokalemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Muscle spasms (72%), arthralgia (16%)</p><p><b>Common</b> (1% to 10%): Pain in extremity, back pain, musculoskeletal chest pain, myalgia, flank pain, musculoskeletal pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia (55%), ageusia (11%)</p><p><b>Common</b> (1% to 10%): Hypogeusia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatic enzymes increased </p><p><b>Postmarketing reports</b>: Drug-induced liver injury<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (40%)</p><p><b>Common</b> (1% to 10%): Pain, asthenia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Elevated blood urea nitrogen<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Erivedge (vismodegib)." Genentech, South San Francisco, CA. </p><h2>More about vismodegib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: hedgehog pathway inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Vismodegib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Basal Cell Carcinoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>